| RT-PCR assay | using | SARS-CoV-2 acid detection kit (count: 2) | |
|---|---|
| TAMRA-3′. The real-time RT-PCR assay was performed using a SARS-CoV-2 nucleic acid detection kit.
-- reference not found! | |
| TAMRA-3′. The RT-PCR assay was performed using a SARS-CoV-2 nucleic acid detection kit.
-- reference not found! | |
| assays | contain | outbreak of COVID-19 (count: 2) | |
| Rapid diagnostic assays, effective treatment and wide use of chest CT will be crucial to contain the worldwide outbreak of COVID-19 in the future.
-- reference not found! | |
| Rapid diagnostic assays, effective treatment and wise use of chest CT will be crucial to contain the worldwide outbreak of COVID-19 in the future.
-- reference not found! | |
| suspension | was used for | RT-PCR assay of SARS-CoV-2 RNA (count: 1) | |
| The suspension was used for RT-PCR assay of SARS-CoV-2 RNA.
-- reference not found! | |
| RT-PCR assay | using | 2019-nCoV kit (count: 1) | |
| RT-PCR assay was preformed using 2019-nCoV specific kit (NC-ORF1ab/N, DAAN GENE, Guangzhou, China).
| |
| primer-probe sets | detect SARS-CoV-2 by | qRT-PCR assay (count: 1) | |
| Various primer-probe sets were previously reported to detect SARS-CoV-2 by the qRT-PCR assay.
-- Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. biorxiv. 2020-02-27. | |
| 2019-nCoV N2 | may | may recommended for qRT-PCR assay (count: 1) | |
| 2019-nCoV_N2, N3 (USA), and NIID_2019-nCOV_N (Japan) sets may be recommended for the sensitive qRT-PCR assay of N region.
-- Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. biorxiv. 2020-02-27. | |
| assay | was based on | 2019-nCoV _ N1 (count: 1) | |
| The moderately sensitive assay was based on 2019-nCoV_N1 (USA) and N (China).
-- Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. biorxiv. 2020-02-27. | |
| 2019-nCoV _ N2 | should | should beneficial for laboratory confirmation by qRT-PCR assay (count: 1) | |
| Therefore, 2019-nCoV_N2, N3 (USA), and NIID_2019-nCOV_N (Japan) sets should be beneficial for the laboratory confirmation of SARS-CoV-2 by qRT-PCR assay of N gene.
-- Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. biorxiv. 2020-02-27. | |
| we | evaluating in | SARS-CoV-2 infection assays (count: 1) | |
| Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays.
-- reference not found! | |
| assays | validate | anti-SARS-CoV-2 effects (count: 1) | |
| Although we mainly conducted in vitro assays to experimentally validate the anti-SARS-CoV-2 effects of olaparib and CVL218 due to limited time, it is natural to speculate that other PARP1 inhibitors may also have antiviral activities against SARS-CoV-2 infection, based on our computational prediction and experimental validation results.
| |
| immunoassay | measures | IgM antibodies to SARS-CoV-2 (count: 1) | |
| The immunoassay quantitatively measures IgM and IgG antibodies to SARS-CoV-2.
-- Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2. medrxiv. 2020-03-16. | |
| neutralization activity | was detected by | sandwich ELISA.SARS-CoV-2-IgG antibody titer (count: 1) | |
| The neutralization activity of the receptorbinding domain (RBD) of antibody in the CP was detected by a sandwich ELISA.SARS-CoV-2-IgG antibody titer was tested by enzyme-linked immunosorbent assay.
-- reference not found! | |
| SARS-CoV-2 RNA | was detected by | RT-PCR assay (count: 1) | |
| SARS-CoV-2 RNA was detected by RT-PCR assay and the result was presented as cycle threshold (Ct) value (Shanghai BioGerm Medical Biotechnology Co., Ltd).
-- reference not found! | |
| AIOD-CRISPR assay system | detect | acids of SARS-CoV-2 (count: 1) | |
| The AIOD-CRISPR assay system was successfully utilized to detect nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV with a sensitivity of few copies.
-- reference not found! | |
| AIOD-CRISPR assay | detect | SARS-CoV-2 (count: 1) | |
| As application examples, the AIOD-CRISPR assay was engineered to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 19 and human immunodeficiency virus type 1 (HIV-1).
-- reference not found! | |
| our AIOD-CRISPR assay | detect | 1.3 copies of SARS-CoV-2 N plasmids (count: 1) | |
| Figure 5B shows that our AIOD-CRISPR assay could detect 1.3 copies of SARS-CoV-2 N plasmids in both real-time and visual detections within 40 min, offering a rapid and nearly single-molecule level sensitive detection.
-- reference not found! | |
| our AIOD-CRISPR assay | be | SARS-CoV-2 detection method (count: 1) | |
| Therefore, our AIOD-CRISPR assay is demonstrated to be a rapid, highly sensitive and specific SARS-CoV-2 detection method.
-- reference not found! | |
| AIOD-CRISPR | has | As assays has developed for SARS-CoV-2 (count: 1) | |
| As proof-of-concept assays, AIOD-CRISPR has been successfully developed for SARS-CoV-2 and HIV-1 detection.
-- reference not found! | |
| LAMP assay | enables | SARS-CoV-2 detection (count: 1) | |
| Although a small number of samples were tested here, the colorimetric LAMP assay enables reliable SARS-CoV-2 detection without sophisticated instrumentation, matching the RT-qPCR performance in field and point-of-care settings.
-- Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. medrxiv. 2020-02-29. | |
| immunoassay | evaluate | value in laboratory diagnosis of COVID-19 (count: 1) | |
| In this study, we used automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to 2019-nCoV, to understand the process of antibody production in disease progression, and to evaluate the value of antibody detection in the laboratory diagnosis of COVID-19.
| |
| confirmed COVID-19 patients | is with | two assay kits (count: 1) | |
| In this study, we tested serum samples from confirmed COVID-19 patients with two assay kits and achieved a high positive rate.
| |
| qRT-PCR assay | using | 2019-nCoV acid detection kit (count: 1) | |
| The qRT-PCR assay was performed using a 2019-nCoV nucleic acid detection kit according to the manufacturer's protocol (Shanghai ZJ Bio-Tech Co Ltd).
| |
| we | used | SARS-CoV-2 spike fusion assay (count: 1) | |
| Therefore, we herein 34 used a SARS-CoV-2 spike (S) protein-mediated cell-cell fusion assay and found that 35 SARS-CoV-2 showed plasma membrane fusion capacity superior to that of 36 SARS-CoV. We solved the X-ray crystal structure of six-helical bundle (6-HB) core 37 of the HR1 and HR2 domains in SARS-CoV-2 S protein S2 subunit, revealing that 38 several mutated amino acid residues in the HR1 domain may be associated with 39 enhanced interactions with HR2 domain.
| |
| Reverse-transcriptase-polymerase-chain-reaction assay | have | have used for diagnosis of COVID-19 patients (count: 1) | |
| Reverse-transcriptase-polymerase-chain-reaction assay (qPCR) with primers and probes targeting the N and ORF1ab genes of SARS-CoV-2 from throat swab samples have been widely used for diagnosis of COVID-19 patients.
| |
| RT-LAMP assays | can detect | low as 100 copies of SARS-CoV-2 RNA (count: 1) | |
| RT-LAMP assays in this study can detect as low as 100 copies of SARS-CoV-2 RNA.
-- reference not found! | |
| we | developed | RT-LAMP assays for detection of SARS-CoV-2 (count: 1) | |
| In conclusion, we developed highly specific RT-LAMP assays for detection of SARS-CoV-2.
-- reference not found! | |
| 62 laboratories | report | results of SARS-CoV-2 assays 63 (count: 1) | |
| To accelerate clinical diagnostic testing for COVID-19 in the 61 United States, the FDA on February 28th, 2020 permitted individual clinically licensed 62 laboratories to report the results of in-house developed SARS-CoV-2 diagnostic assays 63 while awaiting results of an EUA submission for approval 7 .
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| We | approved | 95 CDC assay for detection of SARS-CoV-2 (count: 1) | |
| We next compared the analytic limits of detection (LoD) of the RT-LAMP/Cas12 94 DETECTR assay relative to the US FDA Emergency Use Authorization (EUA)-approved 95 CDC assay for detection of SARS-CoV-2 (Table 1; Fig.
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| we | developed | SARS-CoV-2 DETECTR assay (count: 1) | |
| Here we developed a SARS-CoV-2 DETECTR assay, 154described its performance characteristics and demonstrated compatibility with lateral 155 flow strips.
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| SARS-CoV-2 DETECTR assay | identifies | presence 198 (count: 1) | |
| f) SARS-CoV-2 DETECTR assay identifies presence 198 of SARS-CoV-2 viral RNA from clinical sample.
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| controls | used for | SARS-CoV-2 targets for RNase P. 201LbCas12a detection assays (count: 1) | |
| Positive 200 controls used IVT RNA for SARS-CoV-2 targets and total human RNA for RNase P.201LbCas12a detection assays were run on lateral flow strips (TwistDx) and imaged after 3 202 minutes. (
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| SARS-CoV-2 DETECTR assay | was | evaluated (count: 1) | |
| SARS-CoV-2 DETECTR assay (RT-LAMP + Cas12a) was evaluated on 314 IVT RNA products from SARS-CoV-2, SARS-CoV, bast-SL-CoVZC45, and clinical 315 samples from common human coronaviruses.
-- Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. medrxiv. 2020-03-10. | |
| we | tested RBD from | 2019-nCoV in our assay (count: 1) | |
| Once the sequence was publicly available, we synthesized, cloned and tested the RBD from 2019-nCoV in our assay with human variants of known coronavirus receptors.
| |
| serological assay 249 | is in | detection of SARS-CoV-2 (count: 1) | |
| Although serological assay is a frequently used method for 248 viral infection screening and diagnosis, there are few reports about serological assay 249 in detection of SARS-CoV-2 up to now.
| |
| we | report | application of 250 SARS-CoV-2 N ELISA (count: 1) | |
| In this study, we report the application of the 250 SARS-CoV-2 N protein-based ELISA for detection of IgM and IgG antibodies in the 251 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection.
| |
| 81 isothermal | assay for | 2019-nCoV (count: 1) | |
| 80our knowledge, this is the first report on cross-platform comparison and the evaluation of an 81 isothermal, CRISPR-based assay for 2019-nCoV that's rapid, sensitive and with low 82 instrument requirement.
-- Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus. medrxiv. 2020-02-23. | |
| analytical assessments | suggest | CRISPR-nCoV as assay for 212 2019-nCoV detection (count: 1) | |
| Altogether, 211 these analytical assessments suggest CRISPR-nCoV as a promising molecular assay for 212 2019-nCoV detection with great sensitivity and specificity.
-- Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus. medrxiv. 2020-02-23. | |
| we | demonstrated | assay for 2019-nCoV (count: 1) | |
| 254 Altogether, we demonstrated a CRISPR-based assay for 2019-nCoV that offered shorter 255 turn-around time and great diagnostic value, even in under-resourced settings without the 256 need of thermal cyclers.
-- Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus. medrxiv. 2020-02-23. | |
| assays | were designed282 based on | information on 2019-nCoV (count: 1) | |
| As a result of the rapid outbreak, the targeted assays (PCR and CRISPR) were designed282 and developed based on limited genetic information on 2019-nCoV. Cautions should be taken 283 that certain unknown genomic variations may produce critical impact on the assay efficiency.
-- Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus. medrxiv. 2020-02-23. | |
| We | provide | assay designs for detection of 67 species including SARS-CoV-2 (count: 1) | |
| We provide assay designs for detection of 67 viral species and subspecies, including: SARS-CoV-2, phylogenetically-related viruses, and viruses with similar clinical presentation.
-- CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design. biorxiv. 2020-03-02. | |
| we | tested | SARS-CoV-2 assay (count: 1) | |
| Of our design set, we experimentally screened 4 SARS-CoV-2 designs with a CRISPR-Cas13 detection system and then extensively tested the highest-performing SARS-CoV-2 assay.
-- CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design. biorxiv. 2020-03-02. | |
| SARS-CoV-2 assay | sensitivity of be | may sample types (count: 1) | |
| Among other goals for this work, we plan to evaluate: (1) sensitivity of the SARS-CoV-2 assay against clinical isolates and patient samples-including sputum, throat, and nasal swabs-some of which may be challenging sample types to test; (2) specificity at both the species and subspecies levels against highly related viruses.
-- CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design. biorxiv. 2020-03-02. | |
| findings | provide | evidence for application of antibody assays in diagnosis of COVID-19 patients (count: 1) | |
| These findings provide strong evidence for the routine application of serological antibody assays in the diagnosis and clinical management of COVID-19 patients.
-- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medrxiv. 2020-03-03. | |
| laboratory assay | confirm | SARS-CoV-2 infection (count: 1) | |
| Highly efficient and accurate microbiological laboratory assay is essential to confirm the SARS-CoV-2 infection, rule out other pathogens that can cause CAP, and monitor secondary infections.
-- reference not found! | |
| SARS-CoV test assays | detect for | 4 presence of antibodies to SARS-CoV-2 (count: 1) | |
| We evaluated SARS-CoV test assays to detect for 4 the presence of antibodies to SARS-CoV-2 and tried to determine the timing of appearance of 5 these antibodies by testing serial sera from these patients.
-- reference not found! | |
| two test assays | is with | sera from COVID-19 patients (count: 1) | |
| Results: Cross-reactivity was 8 seen in these two test assays with sera from COVID-19 patients and was detected in 6 out of 7 9 patients from 7 days after onset of symptoms.
-- reference not found! | |
| IgM | can | can detected after infection in COVID-19 by assays (count: 1) | |
| Limitations of this study includes the relatively small number of patients and inconsistent 117 series of sera which ideally should have been collected at a predetermined regular time interval 118 to determine when IgM and IgG can be detected after infection in COVID-19 by these assays.
-- reference not found! | |
| SARS-CoV antibody assays | can detect antibodies in | patients with COVID-19 (count: 1) | |
| 119 We also did not take into account other factors which could cause the delay in development of In conclusion, we provided proof of concept that the available SARS-CoV antibody 133 assays can reliably detect antibodies in patients with COVID-19 which could be used in this 134 current outbreak situation for serosurveys and as a diagnostic tool for under resourced countries.
-- reference not found! | |
| urine samples | gave RT-LAMP signals In | RT-LAMP assay for COVID-19 (count: 1) | |
| In this RT-LAMP assay for COVID-19, the urine samples gave stronger RT-LAMP signals than the serum samples when spiked with identical amounts of COVID-19; however the amount of virus present in an infected individual will likely vary between different biological specimens and over the time course of the infection.
| |
| we | describe | assay for detection of COVID-19 (count: 1) | |
| Here we describe a fast and robust assay for detection of COVID-19 in under 30 minutes.
| |
| patients | performed | RT-PCR assay for SARS-CoV-2 detection 8 (count: 1) | |
| All the patients performed the RT-PCR assay of nasal and pharyngeal swab specimens for SARS-CoV-2 detection 8 .
-- reference not found! | |
| we | developed | assays for detection of SARS-CoV-2 neutralizing (count: 1) | |
| Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike-and nucleocapsid-specific antibodies.
-- reference not found! | |
| PCRconfirmed SARS-CoV-2 infected individuals | revealed by | ELISAs (count: 1) | |
| We demonstrate that most PCRconfirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs.
-- reference not found! | |
| assays | can | can instrumental for detection of SARS-CoV-2-specific antibodies (count: 1) | |
| Overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies.
-- reference not found! | |
| we | used as | antigen test for SARS-CoV-2 antibodies in ELISA format (count: 1) | |
| Since the N protein of SARS-CoV-2 is 90% similar to that of SARS-CoV ( Table 2) , we used SARS-CoV N as an antigen to test for SARS-CoV-2 N-directed antibodies in an ELISA format.
-- reference not found! | |
| we | compared | performance of ELISAs for detection of antibodies among COVID-19 patients (count: 1) | |
| Finally, we compared the performance of the different ELISAs for the detection of antibodies among PCR-confirmed COVID-19 patients to that of PRNT, as the gold standard for CoV serology ( Table 3) .
-- reference not found! | |
| SARS-CoV-2 assays | needed for | contact (count: 1) | |
| Validated SARS-CoV-2 serological assays are currently lacking, yet urgently needed for contact tracing, epidemiological and vaccine evaluation studies.
-- reference not found! | |
| N-ELISA | could detect | SARS-CoV-2-specific antibodies (count: 1) | |
| The N-ELISA could detect SARS-CoV-2-specific antibodies with high specificity and sensitivity.
-- reference not found! | |
| Validation | based | ELISAs for detection of SARS-CoV-2 Infections (count: 1) | |
| Validation of the use of S1 (A,B), receptor binding domain (RBD; C) and nucleocapsid (N; D)based ELISAs for detection of SARS-CoV-2 Infections.
-- reference not found! | |
| sensitivity | specificity of | assays for SARS-CoV-2 (count: 1) | |
| Cohorts used to validate the specificity and sensitivity of assays for SARS-CoV-2
-- reference not found! | |
| assay | detected | fisrt SARS-CoV-2 infection (count: 1) | |
| The proposed assay detected the fisrt SARS-CoV-2 infection in Brazilian Central-West.
| |
| nucleocapsid protein assay | is method for | diagnosis of COVID-19 (count: 1) | |
| CONCLUSIONS Those findings indicate that nucleocapsid protein assay is an accurate, rapid, early and simple method for diagnosis of COVID-19.
-- reference not found! | |
| our N antigen assay | is | diagnosis method of COVID-19 (count: 1) | |
| Those findings indicate that our N antigen assay is an accurate, rapid, early and simple diagnosis method of COVID-19.
-- reference not found! | |
| activity of364 COVID-19 virus M pro | was measured by | assay (count: 1) | |
| Briefly, the activity of364 COVID-19 virus M pro was measured by a continuous kinetic assay, with the substrate 365 MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 (GL Biochem, Shanghai), using wavelengths of 366 320 nm and 405 nm for excitation and emission, respectively.
-- Structure of Mpro from COVID-19 virus and discovery of its inhibitors. biorxiv. 2020-03-10. | |
| RT-PCR assay | using | 2019-nCoV acid detection kit (count: 1) | |
| The real-time RT-PCR assay was performed using a 2019-nCoV nucleic acid detection kit according to the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd).
| |
| iLACO assays | be applied with | with 2019-nCoV threat control (count: 1) | |
| The accuracy, simplicity and versatility of the new developed method suggests that iLACO assays can be conveniently applied with for 2019-nCoV threat control, even in those cases where specialized molecular biology equipment is not available.
| |
| We | performed polymerase extension assays following | addition to mixture of SARS-CoV-2 RdRp (count: 1) | |
| 10 We performed polymerase extension assays with 2'-F,Me-UTP, 3'-F-dTTP, 3'-N 3 -dTTP or TFV-DP + UTP, following the addition of a pre-annealed RNA template and primer to a pre-assembled mixture of the SARS-CoV-2 RdRp (nsp12) and two cofactor proteins (nsp7 and nsp8).
-- reference not found! | |
| we | evaluated | immunoassays for detection of antibodies against 223 SARS-CoV-2 (count: 1) | |
| In this study, we evaluated immunoassays for the detection of antibodies against 223 SARS-CoV-2.
-- reference not found! | |
| ELISAs | detect IgG in | serum samples 225 COVID-19 patients (count: 1) | |
| rN-and rS-based ELISAs were used to detect IgM and IgG in serum samples 225 of confirmed COVID-19 patients.
-- reference not found! | |
| rN-and ELISAs | be | 249 screening method for COVID-19 diagnosis (count: 1) | |
| 248 This study demonstrated that rN-and rS-based ELISAs can be an important 249 screening method for COVID-19 diagnosis, with high sensitivity, especially for the 250 analysis of serum samples from patients after more than 10 d.p.o.
-- reference not found! | |
| rS-based immunoassay | is recommended for | screening of COVID-19 252 patients (count: 1) | |
| However, the 251 rS-based immunoassay is recommended for early screening of suspected COVID-19 252 patients with negative PCR test results.
-- reference not found! | |
| ELISA serodiagnosis | can | can 253 method to RT-PCR for COVID-19 diagnosis (count: 1) | |
| The ELISA serodiagnosis can be a 253 supplementary method to RT-PCR for COVID-19 diagnosis.
-- reference not found! | |
| CR3022 can 99 neutralize SARS-CoV-2 | is in | in assay (count: 1) | |
| Although CR3022 itself cannot 99 neutralize SARS-CoV-2 in this in vitro assay, whether CR3022 can synergize with other 100 SARS-CoV-2 RBD-targeted monoclonal antibodies for neutralization remains to be 101 determined.
-- A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. biorxiv. 2020-03-14. | |
| assay | are the for | 249 2019-nCoV outbreak (count: 1) | |
| Presently, for the 249 2019-nCoV outbreak, nucleic acid-based assay and particular real time PCR, are the
-- Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. medrxiv. 2020-02-14. | |
| kinetics | development of | 1 9 8 assays for COVID-19 (count: 1) | |
| 1 1 useful for studying the kinetics of SARS-CoV-2 replication in vitro and development of 1 9 8 diagnostic assays for COVID-19.
| |
| COVID-19 | was confirmed by | RT-PCR assay (count: 1) | |
| Throat swab sample of the patients was collected and COVID-19 was confirmed by real-time RT-PCR assay using a 2019-nCoV nucleic acid detection kit according to the manufacturer protocol (Shanghai bio-germ Medical Technology Co Ltd) [10] .
| |
| CT scan features | were similar between | pneumonia patients results of SARS-CoV-2 RT-PCR assay (count: 1) | |
| the CT scan features, were similar between pneumonia patients with or without positive results of SARS-CoV-2 RT-PCR assay.
| |
| virus neutralization assay | using | SARS-CoV-2 (count: 1) | |
| Seroconversion was detected by IgG and IgM immunofluorescence using cells expressing the spike protein of SARS-CoV-2 and a virus neutralization assay using SARS-CoV-2 ( Table 3 ).
| |
| RT-PCR assays | detect | 4.8 copies of SARS-CoV-2 (count: 1) | |
| With the assumption of 99% RT-PCR efficiency 20 , we found that RT-PCR assays could detect 4.8 copies of SARS-CoV-2 at 95% probability ( Fig.
-- reference not found! | |
| we | report | development of PCR assay for identification of SARS-CoV-2 infection (count: 1) | |
| Here, we report the development of a multiplex PCR assay for high-sensitivity identification of SARS-CoV-2 infection.
-- reference not found! | |
| COVID-19 RT-LAMP-NBS assay | sensitivity of was | conformity (count: 1) | |
| Furthermore, the sensitivity of COVID-19 RT-LAMP-NBS assay 186 was in conformity with F1ab-and np-RT-LAMP assay (Figure 4, S4 and S5) .
-- reference not found! | |
| COVID-19 RT-LAMP-NBS results | were | 196 197 Specificity of RT-LAMP-NBS assay 198 obtained (count: 1) | |
| 196 197 Specificity of RT-LAMP-NBS assay 198 The positive COVID-19 RT-LAMP-NBS results were obtained only from positive 199 controls (120 copies each of F1ab-plasmid and np-plasmid) (Table S1).
-- reference not found! | |
| COVID-19 RT-LAMP-NBS assay 209 | for % is | 96/96 (count: 1) | |
| The specificity was 100% (96/96) for COVID-19 RT-LAMP-NBS assay 209 among non-COVID-19 patients, which were diagnosed as having pneumonia with 210 confirmed pathogen in clinical laboratory of SanYa People's Hospital.
-- reference not found! | |
| COVID-19 RT-LAMP-BS assay | had | specificity (count: 1) | |
| These 211 preliminary results revealed that the proposed COVID-19 RT-LAMP-BS assay had a 212 high sensitivity and specificity for diagnosis of SARS-CoVepidemic by SARS-CoV-2, starting in last December 2019 in Wuhan,216
-- reference not found! | |
| RT-LAMP | results Compared | 230 with COVID-19 RT-LAMP assays (count: 1) | |
| Compared 230 with the developed COVID-19 RT-LAMP assays, the RT-LAMP results in this report 231
-- reference not found! | |
| COVID-19 RT-LAMP-NBS assay | is | method (count: 1) | |
| Considering these traits, COVID-19 RT-LAMP-NBS 237 assay is a rapid, economical and technically simple method, offering a measure of 238 practicality for field and clinical laboratories, especially for resource-challenged239 settings.
-- reference not found! | |
| our approach | could avoid | results yielded from COVID-19 RT-LAMP assays (count: 1) | |
| Thus, our approach could effectively 248 avoid the undesired results yielded from the developed COVID-19 RT-LAMP assays 249 that only amplified and detected a target gene (e.g.,
-- reference not found! | |
| Regarding | traits of | development of assay for diagnosis of COVID-19 (count: 1) | |
| Thus far, LAMP combined with reverse transcription assay (RT-LAMP) had been developed for the detection of multiple respiratory RNA viruses (e.g., influenza viruses, middle east respiratory syndrome and severe acute respiratory syndrome coronavirus) (12).Regarding these traits of LAMP technique, development of a LAMP-based assay for diagnosis of COVID-19 can overcome the shortcomings posed by rRT-PCR methods, and facilitates rapid diagnosis and surveillance of COVID-19.Up to now, two informal published LAMP assays have been developed for diagnosis of COVID-19, and preliminarily evaluated using clinical or stimulated respiratory samples(13, 14).
-- reference not found! | |
| COVID-19 LAMP assays | detected | sample (count: 1) | |
| Unfortunately, only a genetic sequence (Open reading frame 1a/b; F1ab) was amplified and detected in the two systems, an unreliable diagnosis result may be obtained when the two COVID-19 LAMP assays detected a sample with high homology sequence of SARS-CoV-2 (e.g., bat severe acute 102 respiratory syndrome-like coronavirus, GenBank KY417152.1).
-- reference not found! | |
| we | was challenged by | number of COVID-19 relative to qRT-PCR assays (count: 1) | |
| Therefore, we developed a sensitive, specific, and rapid RT-LAMP assay and its performance was challenged by an extensive number of confirmed COVID-19 (n=47) and negative patients (n=213) relative to qRT-PCR assays approved by two Chinese Food and Drug Administration (qRT-PCR NMPA).
-- reference not found! | |
| medRxiv preprint | was used for | RT-PCR assay of SARS-CoV-2 RNA (count: 1) | |
| 19.20025288 doi: medRxiv preprint was used for RT-PCR assay of SARS-CoV-2 RNA.
| |
| medRxiv preprint sequence | was selected based on | RT-PCR assay for SARS-CoV-2 26 203 (count: 1) | |
| https://doi.org/10.1101/2020.03.05.20031971 doi: medRxiv preprint 9 sequence was selected based on the standard real-time RT-PCR assay for the SARS-CoV-2 26 , 203 which aimed at the RNA-dependent RNA polymerase (RdRp) gene (Supplementary Table 3) .
-- Sensitive one-step isothermal detection of pathogen-derived RNAs. medrxiv. 2020-03-09. | |
| SARS-CoV-2 | was confirmed by | RT-PCR assay (count: 1) | |
| SARS-CoV-2 was confirmed by real-time RT-PCR assay using a SARS-CoV-2 nucleic acid detection kit according to the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd).
| |
| confirmed cases | were based on | SARS-CoV-2 on RT-PCR assay (count: 1) | |
| Admission time for COVID-19 patients was from December 11, 2019 to A total of 3,470 COVID-19 patients were included, of which 3,468 confirmed cases were based on the positive SARS-CoV-2 on RT-PCR assay while two cases 25 were diagnosed according to coronavirus antibody detections.
-- reference not found! | |
| Throat swab samples | using | SARS-CoV-2 RT-PCR assay (count: 1) | |
| Throat swab samples would be collected and tested using the SARS-CoV-2 RT-PCR assay.
-- reference not found! | |
| we | measured | their binding ability to 2019-nCoV RBD by ELISA (count: 1) | |
| Next, we expressed and purified several representative SARS-CoV-specific antibodies which have been reported to target RBD and possess potent neutralizing activities, including m396 [3] , CR3014 [4] , CR3022 [5] , as well as a MERS-CoV-specific human monoclonal antibody m336 developed by our laboratory [15] , and measured their binding ability to 2019-nCoV RBD by ELISA (Figure 1(e)) .
-- reference not found! | |
| laboratories | run RdRp assay with | 2019-nCoV-specific probe (count: 1) | |
| Alternatively, laboratories may choose to run the RdRp assay with only the 2019-nCoV-specific probe.
-- reference not found! | |
| assays | detected | 2019-nCoV (count: 1) | |
| Although both assays detected 2019-nCoV without polymorphisms at oligonucleotide binding sites ( Figure 2 ), we additionally generated in vitro-transcribed RNA standards that exactly matched the sequence of 2019-nCoV for absolute quantification and studying the limit of detection (LOD).
-- reference not found! | |
| 2019-nCoV | detected by | assays (count: 1) | |
| At the present time, the 2019-nCoV has been isolated from patients, detected by specific assays in patients, and cultured in host cells (one available sequence is identified as a passage isolate), starting to fulfill these criteria.
-- Return of the Coronavirus: 2019-nCoV. Viruses. 2020. | |
| it | implement | assays for outbreak management of SARS-CoV-2 (count: 1) | |
| Therefore, it was necessary to rapidly implement adequately quick and sensitive diagnostic assays for outbreak management of SARS-CoV-2 in public health laboratories.
-- reference not found! | |
| details | ran | our SARS-CoV-2 assays (count: 1) | |
| We ordered control material and oligonucleotides (see details below) in week 4 and ran our first SARS-CoV-2 assays on 27 January (week 5).
-- reference not found! | |
| control | was used for | SARS-CoV-2 assay (count: 1) | |
| In addition, the control of LightMix Modular Wuhan CoV RdRP-gene (TibMolbiol, Berlin, Germany) was used for the SARS-CoV-2 specific assay.
-- reference not found! | |
| screening assay | is with | only SARS-CoV-2-specific probe RdRP (count: 1) | |
| Each sample was tested by three PCRs: the screening assay for the E gene and two confirmatory assays targeting the RdRp gene, all performed as recommended in [5] , with either both probes (RdRP_SARSr-P1 and RdRP_SARSr-P2), detecting SARS-CoV and SARS-CoV-2, or only with the SARS-CoV-2-specific probe RdRP_ SARSr-P2 [5] .
-- reference not found! | |
| 73 samples | is with | RealStar SARS-CoV-2 assay (count: 1) | |
| For evaluation of assay performance regarding efficiency, linearity and unspecific signals, we used the SuperScript protocol in a direct comparison of 73 samples with the RealStar SARS-CoV-2 assay.
-- reference not found! | |
| SARS-CoV-2 assays | gave in | 92 % (count: 1) | |
| The specific SARS-CoV-2 assays gave in 67 (92%) identical results (60 negative and seven positive) and six divergent results.
-- reference not found! | |
| prominent challenges | is in | implementation of new SARS-CoV-2 assay (count: 1) | |
| identified the availability of positive control material and primer/probes as well as the lack of skilled personnel and time as the most prominent challenges in the implementation of the new SARS-CoV-2 assay [11] .
-- reference not found! | |
| PCR assays | were performed for | contact investigation around COVID-19 patient (count: 1) | |
| The Public Health Microbiology Laboratory in Bavaria was confronted with SARS-CoV-2-related events very early: once the assays and control materials arrived and the PCR assays were performed for the first time, a large contact investigation around the first German COVID-19 patient (data not shown) was immediately started, with so far more than 700 samples.
-- reference not found! | |
| We | evaluated | performance of assay for detection of SARS-CoV-2 (count: 1) | |
| We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay.
-- reference not found! | |
| None | were detected by | SARS-CoV-2 UCT assay (count: 1) | |
| None of these organisms were detected by the SARS-CoV-2 UCT assay (Table 2) , confirming high specificity of the assay for viruses within the Betacoronavirus subgenus Sarbe covirus [4] .
-- reference not found! | |
| assays | were selected based on | match against 2019-nCoV (count: 1) | |
| Upon the release of the sequence, assays were selected based on the match against 2019-nCoV upon inspection of the sequence alignment.
-- Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. Journal of Clinical Medicine. 2020. | |
| US CDC | shared protocol on | time RT-PCR assay for detection of 2019-nCoV (count: 1) | |
| The US CDC shared the protocol on the real time RT-PCR assay for the detection of the 2019-nCoV with the primers and probes designed for the universal detection of SARS-like coronavirus and the specific detection of 2019-nCoV. However, the protocol has not been validated on other platforms or chemistries apart from the protocol described.
-- Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. Journal of Clinical Medicine. 2020. | |
| 2019-nCoV infection | using | transcription-polymerase chain reaction assay (count: 1) | |
| Of these PUIs, 11 patients have confirmed 2019-nCoV infection using a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay developed by CDC.
-- Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7. | |
| sputum | tested | positive for SARS-CoV-2 by rRT-PCR assay (count: 1) | |
| On January 21, 2020, the TCDC confirmed that the patient's oropharyngeal swab and sputum tested positive for SARS-CoV-2 by rRT-PCR assay.
-- reference not found! | |
| swab | was positive for | SARS-CoV-2 by rRT-PCR assay (count: 1) | |
| Nasopharyngeal swab was positive for SARS-CoV-2 by rRT-PCR assay reported from Taiwan CDC.
-- reference not found! | |
| RT-PCR assays | detect | SARS-CoV-2 (count: 1) | |
| At the present time, RT-PCR assays were most widely used to detect SARS-CoV-2.
-- reference not found! | |
| 2019-nCoV-specific assay | is | needed (count: 1) | |
| A sensitive 2019-nCoV-specific serological assay is needed to firmly assess the rate of past exposure and may help to assess herd immunity.
-- 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. Swiss Med Wkly. 2020. | |
| respiratory specimens | were | collected for SARS-CoV-2 detection by RT-PCR assay (count: 1) | |
| All persons' respiratory specimens were collected for SARS-CoV-2 detection by RT-PCR assay [5] .
-- Transmission of COVID-19 in the terminal stage of incubation period: a familial cluster. International Journal of Infectious Diseases. 2020-03-16. | |
| D assay | using | serum samples from patients with COVID-19 (count: 1) | |
| D) Western-blot confirmatory assay with spike protein RBD using serum samples from patients with COVID-19.
-- reference not found! | |
| COVID-19 acid detection assays | have | have developed (count: 1) | |
| Several COVID-19 nucleic acid detection assays have been developed, both in-house and commercial.
-- The novel coronavirus 2019 epidemic and kidneys. Kidney International. 2020-03-07. | |
| transcription polymerase chain reaction assay | was positive for | 2019-nCoV acid (count: 1) | |
| Real-time reverse transcription polymerase chain reaction assay of the material collected form patient's throat was positive for the 2019-nCoV nucleic acid.
-- reference not found! | |
| potential donor | tested with | RT-PCR assay for SARS-CoV-2 (count: 1) | |
| If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2.
-- Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology & Hepatology. 2020-03-17. | |
| SARS-CoV-2 | is with | real-time RT-PCR assays 4 on Feb 3 (count: 1) | |
| Her respiratory specimens were collected and tested positive for SARS-CoV-2 with real-time RT-PCR assays 4 on Feb 3.
-- reference not found! | |
| acid assay | was developed for | diagnosis of 2019-nCoV infection (count: 1) | |
| 2 Subsequently, collaborations between Chinese and international scientists have rapidly unmasked some additional virological features of 2019-nCoV. A specific viral nucleic acid assay using RT-PCR was quickly developed for the diagnosis of 2019-nCoV infection.
-- What to do next to control the 2019-nCoV epidemic?. The Lancet. 2020-02-14. | |
| RT-PCR assays | are recommended for | diagnosis of SARS-CoV-2 infection (count: 1) | |
| Real-time RT-PCR assays are recommended for diagnosis of SARS-CoV-2 infection.
-- Viral load of SARS-CoV-2 in clinical samples. The Lancet Infectious Diseases. 2020-02-24. | |
| SARS-CoV-2 testing | was positive in | sample by rRTePCR assay (count: 1) | |
| The SARS-CoV-2 testing was positive in the sample of oropharyngeal swabs by rRTePCR assay, whereas other viral respiratory pathogens were all negative.
-- Emergency Caesarean delivery in a patient with confirmed coronavirus disease 2019 under spinal anaesthesia. British Journal of Anaesthesia. 2020-03-17. | |
| RT-PCR assay | is | method applied including SARS-CoV-2 (count: 1) | |
| Therefore, the real-time RT-PCR assay still is a predominant method to be applied for the detection of all kinds of coronaviruses [12, 13] , including SARS-CoV-2 [14] .
-- Recent advances and perspectives of nucleic acid detection for coronavirus. Journal of Pharmaceutical Analysis. 2020-03-01. | |
| RT-PCR 2019-nCoV acid assay | was | positive (count: 1) | |
| Finally, the fourth RT-PCR 2019-nCoV nucleic acid assay was positive.
-- Clinical Features of Atypical 2019 Novel Coronavirus Pneumonia with an initially Negative RT-PCR Assay. Journal of Infection. 2020-02-22. | |
| swabs | using | transcription-polymerase chain reaction assay for SARS-CoV-2 (count: 1) | |
| Two groups of consented patients were sampled using both sampling methods; all swabs were tested using a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay for SARS-CoV-2.
-- Experience of different upper respiratory tract sampling strategies for detection of COVID-19. Journal of Hospital Infection. 2020-03-12. | |
| SARS-CoV-2 PCR protocols | be appropriate | used as in assays (count: 1) | |
| Although LRT specimens originating from SARS-CoV-2 infected patients were not yet available to us, we assume that the novel SARS-CoV-2 PCR protocols for the PF will also be appropriate for LRT specimens, because identical reagents for RNA extraction are used as in the commercially available diagnostic assays for other respiratory viruses (e.g. the PF influenza/RSV assay) [3, 7] .
-- Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion. Journal of Clinical Virology. 2020-04-30. | |